Association between change in body Mass Index, Unified Parkinson's disease rating scale scores, and survival among persons with Parkinson disease secondary analysis of longitudinal data from NINDS

JAMA Neurology

Volumn 73, Issue 3, 2016, Pages 321-328

  Wills, Anne Marie A ^a   Pérez, Adriana ^b   Wang, Jue ^b   Su, Xiao ^b   Morgan, John ^c   Rajan, Suja S ^b   Leehey, Maureen A ^d   Pontone, Gregory M ^e   Chou, Kelvin L ^f   Umeh, Chizoba ^a   Mari, Zoltan ^g   Boyd, James ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUNTINGTON CHOREA; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECONDARY ANALYSIS; SURVIVAL; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT GAIN; WEIGHT REDUCTION; AGED; DISEASE COURSE; MIDDLE AGED; MORTALITY; NATIONAL HEALTH ORGANIZATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; UNITED STATES;

AGED; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84961700554     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4265     Document Type: Article

References (28)

1. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44(1):20-24.
2. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr. 1996;63 (1):130-137.
3. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(2):91-96.
4. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol. 1991;48(8):800-804.
5. Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R. Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry. 1999;67(1): 59-65.
6. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. 2006;67(11): 1955-1959.
7. Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology. 2002;59(7):1051-1057.
8. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol. 2004;159(6): 547-555.
9. Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Body mass index and risk of Parkinson's disease: A prospective cohort study. Am J Epidemiol. 2007;166(10):1186-1190.
10. van der Marck MA, Dicke HC, Uc EY, et al. Body mass index in Parkinson's disease: Ameta-Analysis. Parkinsonism Relat Disord. 2012;18(3):263-267.
11. Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. Ann Neurol. 2003;53(5):676-679.
12. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357(9253): 354-357.
13. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson's disease. Mov Disord. 2006;21(11):1824-1830.
14. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci. 2001;182(2):89-93.
15. Pouwels S, BazelierMT, de Boer A, et al. Risk of fracture in patients with Parkinson's disease. Osteoporos Int. 2013;24(8):2283-2290.
16. Akbar U, He Y, Dai Y, et al. Weight loss and impact on quality of life in Parkinson's disease. PLoS One. 2015;10(5):e0124541.
17. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-Term Parkinson's trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012;27(12):1513-1521.
18. Kieburtz K, Tilley BC, Elm JJ, et al;Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA. 2015;313(6):584-593.
19. Pérez A, Tilley BC. Conduct of stroke-related clinical trials. In: Grotta JC, Albers GW, Broderick JP, et al, eds. Stroke Pathophysiology, Diagnosis, and Management. 6th ed. Amsterdam, Netherlands: Elsevier; 2015:1030-1042
20. Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35(4): 542-571. doi:10.1177/0049124106292364.
21. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374-393. doi:10.1177 /0049124101029003005.
22. Panel on HandlingMissing Data in Clinical Trials; Committee on National Statistics; Division of Behavioral and Social Sciences and Education; National Research Council of the National Academies. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press; 2010:21-37.
23. Toth MJ, Fishman PS, Poehlman ET. Free-living daily energy expenditure in patients with Parkinson's disease. Neurology. 1997;48(1):88-91.
24. Delikanaki-Skaribas E, Trail M, Wong WW, Lai EC. Daily energy expenditure, physical activity, and weight loss in Parkinson's disease patients. Mov Disord. 2009;24(5):667-671.
25. Montaurier C, Morio B, Bannier S, et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain. 2007;130(pt 7):1808-1818.
26. Davies KN, King D, Davies H. A study of the nutritional status of elderly patients with Parkinson's disease. Age Ageing. 1994;23(2):142-145.
27. Schwarzschild MA, Schwid SR, Marek K, et al; Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.
28. Ascherio A, LeWitt PA, Xu K, et al; Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-1468.